Manage Future Cancer Risk, Inform Treatment Decisions Related to PARP Inhibitors1-4

Sources:

  1. Ledermann et al. Lancet Oncol. (2014). 15:852-61.
  2. Kristeleit et al. Presented at European Cancer Congress 2016 (Abstract 8560).
  3. Lheureux et al. J Clin Oncol (2015). 33 (suppl;abstr 5566).
  4. Pujade-Lauraine et al. Lancet Oncol (2017). ttp://dx.doi.org/10.1016/S1470-2045(17)30469-2